Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 19, 2021 at 01:17 pm
Share
Shenzhen New Industries Biomedical Engineering Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 1,225.706 million compared to CNY 970.101 million a year ago. Operating income was CNY 495.500 million compared to CNY 553.349 million a year ago. Net income was CNY 428.611 million compared to CNY 475.729 million a year ago. Basic earnings per share from continuing operations was CNY 0.5466 compared to CNY 0.6637 a year ago.
Shenzhen New Industries Biomedical Engineering Co Ltd is a company engaged in research and development, production and sales of in-vitro diagnostics instruments and supporting reagents. The Company operates three segments, including Instruments and Supporting Software, Reagents, Accessories and Others. Instruments and Supporting Software segment is involved in the production and sales of MAGLUMI automatic chemiluminescence immunoassay analyzer series products and Biossays automatic biochemical analyzer series products. Reagents segment operates the sales of supporting reagents for the analyzers. The products are applied in the examination of Gonads, thyroid gland, glucose metabolism, kidney function and so on. Accessories and Others segment is responsible for the manufacturing and sales of accessories related to in-vitro diagnostics equipment. The Company sells its products both in domestic and international markets, including Asia, Europe, America and Africa.